Lipodystrophy in HIV-infected pediatric patients receiving protease inhibitors

Annals of Pharmacotherapy

Volumn 37, Issue 9, 2003, Pages 1214-1218

  Temple, Mary E ^a   Koranyi, Katalin I ^b   Nahata, Milap C ^b,c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

HIV; Lipodystrophy; Pediatrics; Protease inhibitors

Indexed keywords

AMPRENAVIR; ATORVASTATIN; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDINAVIR; LOPINAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; TRIACYLGLYCEROL;

ADOLESCENT; ANTHROPOMETRIC PARAMETERS; ARTICLE; CHILD; CHILDHOOD DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPODYSTROPHY; MALE; MEDICAL RECORD; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SUBCUTANEOUS FAT DISORDER; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS LOAD;

ADOLESCENT; ANTICHOLESTEREMIC AGENTS; CHILD; CHILD, PRESCHOOL; CHOLESTEROL; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; INFANT; MALE; PROSPECTIVE STUDIES; TIME FACTORS; TRIGLYCERIDES;

EID: 0041422402     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1A444     Document Type: Article

References (26)

1. Kakuda T, Struble K, Piscitelli S. Protease inhibitors for the treatment of human immunodeficiency virus infection. Am J Health Syst Pharm 1998;55:233-54.
2. Centers for Disease Control and Prevention guidelines for the use of antiretroviral agents in pediatric HIV-infections. Atlanta: Centers for Disease Control and Prevention, December 14, 2001.
3. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, et al. A syndrome of peripheral lipodystrophy, hyperlipidemia, and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12:F51-8.
4. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1 protease inhibitor associated peripheral lipodystrophy, hyperlipidemia, and insulin resistance. Lancet 1998;351:1881-3.
5. Carr A, Miller J, Law M, Cooper DA. A syndrome of lipoatrophy, lactic acidemia, and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor related lipodystrophy syndrome (absrtact). AIDS 2000;14:F32.
6. Grinspoon SK. Metabolic complications of antiretroviral therapy. Int AIDS Soc 1999;7:14-9.
7. Echevarria KL, Hardin TC, Smith JA. Hyperlipidemia associated with protease inhibitor therapy. Ann Pharmacother 1999;33:859-63.
8. Saint-Marc T, Partisani M, Poizot-Martin I, Rouviere O, Bruno F, Avellaneda R, et al. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study. AIDS 2000;14:37-49.
9. Struble K, Piscitelli S. Syndromes of abnormal fat redistribution and metabolic complications in HIV-infected patients. Am J Health Syst Pharm 1999;56:2343-8.
10. Thomas JC, Virella-Lopez MF, Del Bene VE, Cerveny JD, Taylor KB, McWhorter LS, et al. Use of fenofibrate in the management of protease inhibitor associated lipid abnormalities. Pharmacotherapy 2000;20:727-34.
11. Walli R, Herfort O, Michl GM, Demant T, Jager H, Dieterle C, et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired glucose tolerance in HIV-1 infected patients. AIDS 1998;12:F167-73.
12. Yarasheki KE, Tebas P, Sigmund C, Dagogo-Jack S, Bohrer A, Turk J, et al. Insulin resistance in HIV protease inhibitor-associated diabetes. J Acquir Immune Defic Syndr 1999;21:209-16.
13. Safrin S, Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection. AIDS 1999;13:2493-505.
14. Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M. Buffalo hump in HIV-1 infection. Lancet 1998;351:867-70.
15. Miller KD, Jones E, Yanovski JA, Shankar R, Feuerstein I, Falloon J. Visceral abdominal fat accumulation associated with the use of indinavir. Lancet 1998;351:871-5.
16. Viraben R, Aquilina C. Indinavir-associated lipodystrophy. AIDS 1998; 12:F37-9.
17. Roth VR, Kravcik S, Angel JB. Development of cervical fat pads following therapy with human immunodeficiency virus type 1 protease inhibitors. Clin Infect Dis 1998;27:65-7.
18. Striker R, Conlin D, Marx M, Wiviott L. Localized adipose tissue hypertrophy in patients receiving human immunodeficiency virus protease inhibitors. Clin Infect Dis 1998;98:218-20.
19. Wedekind CA, Pugatch D. Lipodystrophy syndrome in children infected with human immunodeficiency virus. Pharmacotherapy 2001;21:861-6.
20. Arpadi SM, Cuff PA, Horlick M, Wang J, Kotler DP. Lipodystrophy in HIV-infected children is associated with high viral load and low CD4+ lymphocyte count and CD4+ lymphocyte percentage at baseline and use of protease inhibitors and stavudine. J Acquir Immune Defic Syndr 2001;27:30-4.
21. Jaquet D, Levine M, Ortega-Rodriguez F, Faye A, Polak M, Vilmer E, et al. Clinical and metabolic presentation of lipodystrophy syndrome in children. AIDS 2000;14:2123-8.
22. Barlow SE, Dietz WH, Klish WJ, Trowbridge FL. Medical evaluation of overweight children and adolescents: a needs assessment of health practitioners. Pediatrics 2002;110:222-8.
23. Pujol RM, Domingo P, Guiu XM, Francia E, Sanbeat MA, Alomar A, et al. HIV-1 protease inhibitor associated partial lipodystrophy: clinicopathologic review of 14 cases. J Am Acad Dermatol 2000;42:193-8.
24. Brambilla P, Bricalli D, Sala N, Renzetti F, Manzoni P, Vanzulla A, et al. Highly active antiretroviral treated HIV-infected children show fat distribution changes even in the absence of lipodystrophy. AIDS 2001;15: 2415-22.
25. Lainka E, Oezbek S, Falck M, Ndagijimana J, Niehues T. Marked dyslipidemia in human immunodeficiency virus-infected children on protease inhibitor-containing antiretroviral therapy. Pediatrics 2002; 110: e56-e66.
26. Amaya RA, Kozinetcz CA, McMean A, Schwarzwald A, Kline MW. Lipodystrophy syndrome in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2002;21:405-10.